Cardiology: Advancing Cardiovascular Health Through Science, Scale, and Sustainable Innovation:

At AMOLYT LIFESCIENCES, cardiology represents the cornerstone of our strategic and societal mandate. Cardiovascular disease remains the leading cause of mortality in India, accounting for millions of deaths annually and exerting profound economic and social impact. Addressing this challenge is both a moral imperative and a long-term growth priority for our organization.

We are committed to transforming cardiovascular care for India’s 1.4 billion people while contributing meaningfully to global cardiovascular health standards. Our cardiology strategy is built on the convergence of cutting-edge medical science, India-centric innovation, and scalable access models, enabling us to address the full spectrum of cardiovascular risk—from prevention and early intervention to advanced disease management.

Our initiatives align closely with India’s national priorities, including the National Programme for Prevention and Control of Non-Communicable Diseases (NPCDCS), Pradhan Mantri Jan Arogya Yojana (PMJAY), and the Ayushman Bharat Digital Mission (ABDM), while remaining harmonized with global clinical guidance from the , the , the , and the . Through this dual alignment, we are helping reposition India from a high-burden cardiovascular geography into a global engine of cardiac innovation.

Corporate Vision and Strategic Imperatives

Our vision is clear and resolute: to substantially reduce cardiovascular morbidity and mortality by enabling early risk identification, precision-guided therapy, and sustained disease control for every patient—regardless of geography or income level.

To achieve this, we are executing a disciplined set of strategic imperatives:

Portfolio Leadership Across the Cardiovascular Continuum

We have built and continue to expand a comprehensive cardiology portfolio encompassing:

• Advanced lipid-lowering therapies, including high-intensity statins, combination therapies, and PCSK9 inhibitors
• Comprehensive heart failure solutions across the ejection fraction spectrum, incorporating SGLT2 inhibitors, ARNI therapy, mineralocorticoid receptor antagonists, and metabolic modulators
• Antiplatelet and antithrombotic therapies for acute coronary syndromes, percutaneous coronary interventions, and atrial fibrillation
• Emerging RNA-based and targeted therapies addressing complex dyslipidemias and residual cardiovascular risk
• Each therapy is developed and deployed with a strong emphasis on clinical evidence, long-term outcomes, patient adherence, and real-world effectiveness in Indian populations.

India-Centric Innovation with Global Standards

We are investing significantly in India-anchored research and development programs, including large, polygenic clinical trials designed to meet USFDA, EMA, PMDA, TGA, and ANVISA standards. This approach accelerates access to innovation while maintaining global regulatory rigor.bridge long-standing access gaps.

Integrated Care and Access at Scale

Through partnerships with over 10,000 hospitals, cardiac centers, and clinics, we support an integrated cardiovascular care ecosystem capable of reaching tens of millions of patients annually, strengthening access to advanced care beyond metropolitan centers.

Digital and AI-Enabled Cardiac Care

By embedding artificial intelligence, digital diagnostics, remote monitoring, and virtual rehabilitation into cardiovascular pathways, we aim to reduce diagnostic delays, improve treatment adherence, and significantly lower post-event mortality and rehospitalization rates.

Demonstrated Impact and Clinical Excellence

Our cardiology strategy is anchored in execution and measurable outcomes:

Expanded Access to Advanced Therapies: Deployment of combination lipid-lowering therapies, heart failure regimens, and antiplatelet solutions has supported millions of patients annually, contributing to significant reductions in major adverse cardiovascular events and post-acute complications.

Population-Level Prevention Programs: Nationwide prevention and secondary prophylaxis initiatives have improved long-term adherence and reduced recurrent cardiovascular and cerebrovascular events in high-risk populations.

Digital Transformation of Cardiac Diagnostics: AI-enabled ECG platforms, tele-cardiology networks, and rapid biomarker diagnostics have strengthened early detection, enabled faster referrals, and reduced urban–rural care gaps.

These achievements reflect our ability to deliver clinical excellence at scale while maintaining affordability and sustainability.

Navigating a Complex Cardiovascular Landscape

India’s cardiovascular burden is shaped by rising diabetes prevalence, uncontrolled hypertension, lifestyle transitions, environmental factors, and genetic susceptibility. High out-of-pocket expenditure, delayed diagnosis, and uneven access to advanced interventions continue to challenge outcomes.

We address these challenges through:

• Evidence-based prevention and early screening initiatives
• Responsible use of combination and long-term therapies
• Strengthened supply chains and digital infrastructure
• Continuous engagement with clinicians, policymakers, and public health institutions
• Enduring Commitment and Future Outlook

Guided by our core values of scientific excellence, ethical governance, patient-centricity, and collaborative partnership, we are making sustained long-term investments to advance cardiovascular research, manufacturing, and access.

Through strategic collaboration with institutions such as the , the , global academic partners, and leading medtech innovators, we continue to strengthen pharmacovigilance, accelerate translational research, and expand advanced cardiac care delivery.

Our ambition is both measurable and enduring: to meaningfully improve cardiovascular outcomes for hundreds of millions of patients by 2035, reduce disease-related disability and mortality, and establish India as a global reference point for cardiology innovation.

Because advancing heart health is not only about extending life—it is about preserving vitality, productivity, and the promise of a healthier future.